Search

file (3)

Publication Library

Publication Library

HOMEPublication Library

2025.May.23

Prodrug

Potentiation of AKR1C3- and P53-dependent AST-3424 activity via PUMA-mediated degradation of Rad51

Poster

2025.May.23

Prodrug

Preclinical evaluation of the AKR1C3-activated alkylator, OBI-3424, in hepatoblastoma – A report from the Pediatric Preclinical In Vivo Testing Consortium (PIVOT)

Poster

2025.May.01

ADC

OBI-992, a Novel TROP2 Antibody-Drug Conjugate, Exhibits Distinct Resistance Profiles Compared to other TROP2 Targeting ADCs

Poster

2025.May.01

ADC

OBI-902, a Novel TROP2-Targeted Antibody-Drug Conjugate via GlycOBI® Platform, Has Favorable Pharmacokinetics and Sustained Antitumor Activities in Challenging Solid Tumors

Poster

2025.May.01

Technology

Harnessing the GlycOBI® Enabling Technologies: Next-generation Site-Specific Glycan ADCs with Versatile DAR to Enhance Therapeutic Index

Poster

2025.May.01

Technology

ThiOBI® Platform, a Novel Hydrophilic Linker for Irreversible Cysteine-selective Biomolecular Conjugation, Demonstrated Potent and Durable Antitumor Activities in Various Animal Models

Poster

2025.Mar.14

ADC

Preclinical Evaluation of a Novel Antibody-Drug Conjugate OBI-992 for Cancer Therapy

Article

2024.Dec.04

ADC

OBI-992, a Novel TROP2-Targeted Antibody–Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models

Article

2024.Sep.23

Vaccine

Phase I–II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors

Article

2024.Aug.20

Technology

High-Efficiency Homogeneous ADC Platform by Endoglycosidase Sz Provides Insights into Its Transglycosylation Mechanism

Poster